The Importance of Explainable AI in Medicine
A study highlights the need for clear AI explanations in clinical settings.
Murray H Loew, D. Provenzano, S. Haji-Momenian, V. Batheja
― 6 min read
Table of Contents
The use of artificial intelligence (AI) in medicine is increasing. As AI becomes more common in healthcare, there is a growing need for ways to explain how these AI systems work. This is especially important in clinical medicine, where doctors need to trust AI's decisions. However, many current methods for explaining AI models have issues, and it is critical to find better approaches that can show clearly how these systems reach their conclusions.
Explainable AI
The Need forMany current AI methods focus on interpreting the results after the model has made its predictions. These methods can sometimes give unclear or incorrect explanations about what the model is doing. A known problem is that these methods do not provide solid numbers to show how understandable or reliable they are. Without these solid numbers, there is a big gap between what the AI developers want to explain and what the doctors need to know about the AI’s decisions. This gap shows just how important it is to have measurable ways to explain AI models.
In one study, a team proposed guidelines for explainable AI specifically for Medical Imaging. They suggested that any method should meet five key criteria: it should be easy to understand, clinically relevant, truthful, informative, and efficient. However, the study found that no popular AI explanation method met all of these standards. This highlights the need for a new method that could satisfy all these requirements.
Current AI Explanation Methods
Some popular methods for explaining AI models include SHAP, LIME, and GradCAM. These methods are designed to analyze the features the model uses to make decisions. For example, GradCAM looks at the features produced by deep learning networks to create a visual map showing which parts of an image are important for the model's predictions. However, these current methods can still struggle with some issues. They may not accurately pinpoint where in the image the model is focused, especially when it comes to images with multiple features or overlapping targets.
In early tests, researchers found that one way to improve these weaknesses was to look at the most important feature produced by the model instead of relying on the entire feature map. This study aimed to turn the most important feature map into a way of measuring how well the AI explains itself, specifically looking at whether it identifies the correct areas in medical images related to Prostate Cancer.
Data and Model Preparation
To test this new method, researchers used a public database of prostate MRI scans. This database contains hundreds of scans that have already been analyzed by doctors to find cancerous areas. The team focused on specific images that showed different types of prostate lesions and worked to create a balanced dataset that included both cancerous and non-cancerous lesions.
They used different types of neural network models to learn from the data. By training these models on different sets of images, they could then test how well the models performed. This involved splitting the data into groups to ensure accuracy and to allow for a thorough evaluation of the models’ performance.
Generating Features and Testing
Once the models were trained, researchers generated Feature Maps to see which areas of the images were most significant for the models. They identified the most important feature maps to look for signs of prostate lesions in the MRI scans. The goal was to see how well these feature maps could indicate the correct localization of the lesions, based on their position in the image.
To ensure the results were not due to chance, the team performed tests by scrambling the labels of the images and checking if the models could still perform well. This helped confirm whether the models were genuinely learning to identify lesions or if their success was simply a matter of randomness.
Comparing Methods
The team then compared their findings with the results from GradCAM, looking at how well both methods localized the lesions in the images. Interestingly, the most important feature map was able to correctly identify lesion locations much more effectively compared to GradCAM.
In their observations, most models performed well when they were trained and tested on similar types of images. For example, when models were trained on images containing the prostate, they were more accurate than when they were tested on different types of images. This suggested that using the right type of data for training the model can greatly affect the results.
Results and Observations
As the study progressed, the team observed that models trained on complete sets of images were often good at finding lesions, but they sometimes relied on areas outside the prostate. This raised questions about whether the models were truly learning to find cancer or if they were detecting patterns from unrelated parts of the images. By examining the results when the prostate was removed from the images, researchers could see how much of the model's success came from the actual prostate tissue versus other areas.
The models showed high success rates in identifying lesions, particularly when using Transfer Learning-a method where a model trained on a larger dataset is then adapted to a smaller, specific dataset. This approach helped to improve accuracy and localization rates.
Challenges and Limitations
While the study showed promising results, there were limitations to consider. Using only the most important feature map meant that potential insights from other significant regions might be overlooked. The coding framework used to identify these features might also vary depending on different programming tools, which could affect replication of results.
Additionally, the dataset used for the study was relatively small. Having a more extensive dataset would provide better validation for the methods and their effectiveness in real-world scenarios.
Implications for Real-World Applications
The findings from this study have significant implications for how AI is used in medical imaging. As doctors increasingly rely on AI to assist in diagnosing conditions like cancer, it is crucial for these AI systems not only to make accurate predictions but also to clarify how they arrived at those decisions. Understanding which areas of an image are significant helps to build trust between AI systems and healthcare professionals.
In summary, the research points to the importance of explainability in AI, particularly in clinical settings. A clear measure of how well an AI model can localize features of interest can serve as a useful tool. This helps ensure that AI models are focusing on the correct anatomical areas, making them more reliable in practical applications.
Future Directions
As the field of AI continues to grow, further studies are needed to refine the metrics used for explainability. Research should focus on expanding the criteria for what makes an explanation satisfactory. This includes exploring additional features that could be important in different contexts and testing new methods for validating the accuracy of AI predictions.
Overall, the aim should be to create AI systems that are not only effective in their predictions but also offer clear insights into the decision-making process. Doing so will lead to better integration of AI tools in healthcare, ultimately benefiting patients and improving outcomes in medical practice.
Title: Exploring the Explainability of a Machine Learning Model for Prostate Cancer: Do Lesions Localize with the Most Important Feature Maps?
Abstract: As the use of AI grows in clinical medicine, so does the need for better explainable AI (XAI) methods. Model based XAI methods like GradCAM evaluate the feature maps generated by CNNs to create visual interpretations (like heatmaps) that can be evaluated qualitatively. We propose a simple method utilizing the most important (highest weighted) of these feature maps and evaluating it with the most important clinical feature present on the image to create a quantitative method of evaluating model performance. We created four Residual Neural Networks (ResNets) to identify clinically significant prostate cancer on two datasets (1. segmented prostate image and 2. full cross sectional pelvis image (CSI)) and two model training types (1. transfer learning and 2. from-scratch) and evaluated the models on each. Accuracy and AUC was tested on one final full CSI dataset with the prostate tissue removed as a final test set to confirm results. Accuracy, AUC, and co-localization of prostate lesion centroids with the most important feature map generated for each model was tabulated and compared to co-localization of prostate lesion centroids with a GradCAM heatmap. Prostate lesion centroids co-localized with any model generated through transfer learning [≥]97% of the time. Prostate lesion centroids co-localized with the segmented dataset 86 > 96% of the time, but dropped to 10% when segmented model was tested on the full CSI dataset and 21% when model was trained and tested on the full CSI dataset. Lesion centroids co-localized with GradCAM heatmap 98% > 100% on all datasets except for that trained on the segmented dataset and tested on full CSI (73%). Models trained on the full CSI dataset performed well (79% > 89%) when tested on the dataset with prostate tissue removed, but models trained on the segmented dataset did not (50 > 51%). These results suggest that the model trained on the full CSI dataset uses features outside of the prostate to make a conclusion about the model, and that the most important feature map better reflected this result than the GradCAM heatmap. The co-localization of medical region of abnormality with the most important feature map could be a useful quantitative metric for future model explainability.
Authors: Murray H Loew, D. Provenzano, S. Haji-Momenian, V. Batheja
Last Update: 2024-10-14 00:00:00
Language: English
Source URL: https://www.medrxiv.org/content/10.1101/2024.10.12.24315347
Source PDF: https://www.medrxiv.org/content/10.1101/2024.10.12.24315347.full.pdf
Licence: https://creativecommons.org/licenses/by-nc/4.0/
Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.
Thank you to medrxiv for use of its open access interoperability.